← All X4 Pharmaceuticals, INC filings

X4 Pharmaceuticals, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
XFOR
X4 Pharmaceuticals, INC
10-K: X4 Pharma Shifts Focus to Chronic Neutropenia, Boosts Capital
X4 Pharmaceuticals details a strategic pivot towards chronic neutropenia, significant capital raises, and management changes in its 2025 annual report.
NASDAQ
XFOR
X4 Pharmaceuticals, INC
10-K: X4 Pharmaceuticals Reports 2024 Results, Outlines Strategic Restructuring
X4 Pharmaceuticals details its 2024 financial performance and announces a strategic restructuring to prioritize mavorixafor development and optimize XOLREMDI commercialization.
NASDAQ
XFOR
X4 Pharmaceuticals, INC
10-K: X4 Pharmaceuticals Seeks Approval for Mavorixafor, Eyes Potential 2024 Launch
X4 Pharmaceuticals is seeking FDA approval for mavorixafor to treat WHIM syndrome, with a potential launch in the second quarter of 2024.